These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 31115038)

  • 1. Impact of ruxolitinib on myelofibrosis patients post allogeneic stem cell transplant-a pilot study.
    Pu JJ; Poulose J; Malysz J; Zhu J; Fanburg-Smith JC; Claxton DF; Bayerl MG
    Br J Haematol; 2019 Sep; 186(5):e130-e133. PubMed ID: 31115038
    [No Abstract]   [Full Text] [Related]  

  • 2. JAK inhibition with ruxolitinib as pretreatment for allogeneic stem cell transplantation in primary or post-ET/PV myelofibrosis.
    Stübig T; Alchalby H; Ditschkowski M; Wolf D; Wulf G; Zabelina T; Wolschke C; Ayuk F; Kröger N
    Leukemia; 2014 Aug; 28(8):1736-8. PubMed ID: 24569777
    [No Abstract]   [Full Text] [Related]  

  • 3. Janus Kinase Inhibitors and Stem Cell Transplantation in Myelofibrosis.
    El Fakih R; Popat U
    Clin Lymphoma Myeloma Leuk; 2015 Jun; 15 Suppl():S34-42. PubMed ID: 26297276
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Janus kinase inhibitors and allogeneic stem cell transplantation for myelofibrosis.
    Gupta V; Gotlib J; Radich JP; Kröger NM; Rondelli D; Verstovsek S; Deeg HJ
    Biol Blood Marrow Transplant; 2014 Sep; 20(9):1274-81. PubMed ID: 24680977
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Allogeneic hematopoietic cell transplantation for myelofibrosis in patients pretreated with the JAK1 and JAK2 inhibitor ruxolitinib.
    Jaekel N; Behre G; Behning A; Wickenhauser C; Lange T; Niederwieser D; Al-Ali HK
    Bone Marrow Transplant; 2014 Feb; 49(2):179-84. PubMed ID: 24292520
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Practical management of myelofibrosis with ruxolitinib.
    Ho PJ; Marlton P; Tam C; Stevenson W; Ritchie D; Bird R; Dunlop LC; Durrant S; Ross DM
    Intern Med J; 2015 Dec; 45(12):1221-30. PubMed ID: 26648193
    [TBL] [Abstract][Full Text] [Related]  

  • 7. How We Manage Myelofibrosis Candidates for Allogeneic Stem Cell Transplantation.
    Polverelli N; Farina M; D'Adda M; Damiani E; Grazioli L; Leoni A; Malagola M; Bernardi S; Russo D
    Cells; 2022 Feb; 11(3):. PubMed ID: 35159362
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A retrospective comparison of conventional intensity conditioning and reduced-intensity conditioning for allogeneic hematopoietic cell transplantation in myelofibrosis.
    Gupta V; Kröger N; Aschan J; Xu W; Leber B; Dalley C; Sabloff M; Lipton JH; Messner H; Brune M
    Bone Marrow Transplant; 2009 Sep; 44(5):317-20. PubMed ID: 19234505
    [No Abstract]   [Full Text] [Related]  

  • 9. A case-based discussion of clinical problems in the management of patients treated with ruxolitinib for myelofibrosis.
    Ho PJ; Bajel A; Burbury K; Dunlop L; Durrant S; Forsyth C; Perkins AC; Ross DM
    Intern Med J; 2017 Mar; 47(3):262-268. PubMed ID: 28260257
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Prospective Pilot Study of Graft-versus-Host Disease Prophylaxis with Post-Transplantation Cyclophosphamide and Ruxolitinib in Patients with Myelofibrosis.
    Morozova EV; Barabanshikova MV; Moiseev IS; Shakirova AI; Barhatov IM; Ushal IE; Rodionov GG; Moiseev SI; Surkova EA; Lapin SV; Vlasova JJ; Rudakova TA; Darskaya EI; Baykov VV; Alyanski AL; Bondarenko SN; Afanasyev BV
    Acta Haematol; 2021; 144(2):158-165. PubMed ID: 32325461
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Circulating megakaryocyte and platelet microvesicles correlate with response to ruxolitinib and distinct disease severity in patients with myelofibrosis.
    Barone M; Ricci F; Sollazzo D; Ottaviani E; Romano M; Auteri G; Bartoletti D; Reggiani MLB; Vianelli N; Tazzari PL; Cavo M; Forte D; Palandri F; Catani L
    Br J Haematol; 2019 Jun; 185(5):987-991. PubMed ID: 30450539
    [No Abstract]   [Full Text] [Related]  

  • 12. [Successful management of splenomegaly with ruxolitinib prior to allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia transformed from post-polycythemia vera myelofibrosis].
    Fujishima M; Fujishima N; Kitadate A; Guo Y; Watanabe A; Ubukawa K; Nara M; Yoshioka T; Kameoka Y; Takahashi N
    Rinsho Ketsueki; 2017; 58(7):743-748. PubMed ID: 28781268
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Allogeneic haematopoietic cell transplantation for myelofibrosis: a real-life perspective.
    Savani M; Dulery R; Bazarbachi AH; Mohty R; Brissot E; Malard F; Bazarbachi A; Nagler A; Mohty M
    Br J Haematol; 2021 Nov; 195(4):495-506. PubMed ID: 33881169
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Ruxolitinib as a bridge to allogeneic hematopoietic cell transplantation in a patient with idiopathic myelofibrosis].
    Barba P; Fox ML; Blanco A; Valcárcel D
    Med Clin (Barc); 2015 Feb; 144(4):184-5. PubMed ID: 24952663
    [No Abstract]   [Full Text] [Related]  

  • 15. Medication adherence among allogeneic hematopoietic stem cell transplant recipients: a pilot single-center study.
    Lehrer J; Brissot E; Ruggeri A; Dulery R; Vekhoff A; Battipaglia G; Giannotti F; Fernandez C; Mohty M; Antignac M
    Bone Marrow Transplant; 2018 Feb; 53(2):231-233. PubMed ID: 29155420
    [No Abstract]   [Full Text] [Related]  

  • 16. Role of hematopoietic stem cell transplantation in patients with myeloproliferative disease.
    Salit RB; Deeg HJ
    Hematol Oncol Clin North Am; 2014 Dec; 28(6):1023-35. PubMed ID: 25459177
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of prior JAK-inhibitor therapy with ruxolitinib on outcome after allogeneic hematopoietic stem cell transplantation for myelofibrosis: a study of the CMWP of EBMT.
    Kröger N; Sbianchi G; Sirait T; Wolschke C; Beelen D; Passweg J; Robin M; Vrhovac R; Helbig G; Sockel K; Conneally E; Rubio MT; Beguin Y; Finke J; Bernasconi P; Morozova E; Clausen J; von dem Borne P; Schaap N; Schroyens W; Patriarca F; Di Renzo N; Yeğin ZA; Hayden P; McLornan D; Yakoub-Agha I
    Leukemia; 2021 Dec; 35(12):3551-3560. PubMed ID: 34023851
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of Molecular Genetics on Outcome in Myelofibrosis Patients after Allogeneic Stem Cell Transplantation.
    Kröger N; Panagiota V; Badbaran A; Zabelina T; Triviai I; Araujo Cruz MM; Shahswar R; Ayuk F; Gehlhaar M; Wolschke C; Bollin R; Walter C; Dugas M; Wiehlmann L; Lehmann U; Koenecke C; Chaturvedi A; Alchalby H; Stadler M; Eder M; Christopeit M; Göhring G; Koenigsmann M; Schlegelberger B; Kreipe HH; Ganser A; Stocking C; Fehse B; Thol F; Heuser M
    Biol Blood Marrow Transplant; 2017 Jul; 23(7):1095-1101. PubMed ID: 28389256
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Peritransplantation Use of Ruxolitinib in Myelofibrosis.
    Ibrahim U; Petrone GEM; Mascarenhas J; Keyzner A
    Biol Blood Marrow Transplant; 2020 Dec; 26(12):2177-2180. PubMed ID: 32818555
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of ruxolitinib pretreatment on outcomes after allogeneic stem cell transplantation in patients with myelofibrosis.
    Shahnaz Syed Abd Kadir S; Christopeit M; Wulf G; Wagner E; Bornhauser M; Schroeder T; Crysandt M; Mayer K; Jonas J; Stelljes M; Badbaran A; Ayuketang Ayuk F; Triviai I; Wolf D; Wolschke C; Kröger N
    Eur J Haematol; 2018 Sep; 101(3):305-317. PubMed ID: 29791053
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.